Welcoming you for any type of article submission for the upcoming issue on/before February 26, 2021.


Review Article
Volume 5 Issue 11 - 2020
The Application of Fullerene Derivatives in Medicine and Specific Endocrinological Conditions
Nicholas A Kerna1*, John V Flores2,3 and Kevin D Pruitt4, Uzoamaka Nwokorie5 and Hilary M Holets2,3
1SMC–Medical Research, Thailand
2Beverly Hills Wellness Surgical Institute, USA
3Orange Partners Surgicenter, USA
4Kemet Medical Consultants, USA
4University of Washington, USA
*Corresponding Author: Nicholas A Kerna, POB47 Phatphong, Suriwongse Road, Bangkok, Thailand 10500.
Received: September 15, 2020; Published: October 29, 2020




Abstract

Fullerene derivatives have select properties that have attracted investigation regarding applications in medicine. For the most part, they have demonstrated high biocompatibility and low toxicity in humans and animals. They have shown antimicrobial, antiviral, and antioxidant properties, and act as an ROS-scavenger. Specific fullerene derivatives are being considered in treating multiple sclerosis, skin disorders, HIV infection, cancer, ischemia, and osteoporosis. They have shown a potential for applications in dermatology, treating acne vulgaris and erythema. Specific fullerene derivatives are used as a synergistic agent in diagnostic imaging, biosensing, drug-delivery, targeted therapy, and theranostic procedures. Exposure to certain fullerene materials can be hazardous to human health, particularly as potential endocrine disruptors. Nevertheless, fullerene derivatives are showing promise in their adjunctive application in medicine and specific endocrinological disorders.

Keywords: Antioxidant; Biocompatibility; Biosensing; Diagnostic Imaging; Drug-Delivery; Endocrinological Disorders; Fullerene

References

  1. Bosi S., et al. “Fullerene derivatives: An attractive tool for biological applications”. European Journal of Medicinal Chemistry 38-11-12 (2003): 913-923. https://www.researchgate.net/publication/8988373_Fullerene_Derivatives_An_Attractive_Tool_for_Biological_Applications
  2. Yadav BC and Kumar R. “Structure, properties and applications of fullerenes”. International Journal of Nanotechnology and Applications ISSN (2008). https://www.researchgate.net/publication/233816061_Structure_properties_and_applications_of_fullerene
  3. “Fullerenes: principles and applications”. Choice Reviews Online (2007).
  4. Jensen AW., et al. “Biological applications of fullerenes”. Bioorganic and Medicinal Chemistry6 (1996): 767-779. https://pubmed.ncbi.nlm.nih.gov/8818226/
  5. Tsao N., et al.In vitro action of carboxyfullerene”. Journal of Antimicrobial Chemotherapy4 (2002): 641-649. https://academic.oup.com/jac/article/49/4/641/718791
  6. Mashino T., et al. “Inhibition of E. coli growth by fullerene derivatives and inhibition mechanism”. Bioorganic and Medicinal Chemistry Letters20 (1999): 2959-2962. https://pubmed.ncbi.nlm.nih.gov/10571155/
  7. Deryabin DG., et al. “The activity of [60] fullerene derivatives bearing amine and carboxylic solubilizing groups against Escherichia coli: A comparative study”. Journal of Nanomaterials (2014). https://www.hindawi.com/journals/jnm/2014/907435/
  8. Mashino T., et al. “Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives”. Bioorganic and Medicinal Chemistry Letters4 (2005): 1107-1109. https://pubmed.ncbi.nlm.nih.gov/15686922/
  9. Yang B., et al. “Reactive oxygen species (ROS)-based nanomedicine”. Chemical Reviews8 (2019): 4881-4985. https://pubs.acs.org/doi/10.1021/acs.chemrev.8b00626
  10. Dugan LL., et al. “Carboxyfullerenes as neuroprotective antioxidants”. In: Pharmacology of Cerebral Ischemia 1998 (1999).
  11. Daroczi B., et al.In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model”. Clinical Cancer Research (2006): 9434-9439. https://www.pnas.org/content/94/17/9434
  12. Dellinger A., et al. “Fullerene nanomaterials inhibit phorbol myristate acetate-induced inflammation”. Experimental Dermatology12 (2009): 1079-1081. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955253/
  13. Basso AS., et al. “Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis”. Journal of Clinical Investigation4 (2008): 1532-1543. https://pubmed.ncbi.nlm.nih.gov/18340379/
  14. Mousavi SZ., et al. “Fullerene nanoparticle in dermatological and cosmetic applications”. Nanomedicine: Nanotechnology, Biology, and Medicine3 (2017): 1071-1087. https://www.sciencedirect.com/science/article/abs/pii/S1549963416301721
  15. Bosi S., et al. “Synthesis and anti-HIV properties of new water-soluble bis- functionalized[60]fullerene derivatives”. Bioorganic and Medicinal Chemistry Letters24 (2003): 4437-4440. https://pubmed.ncbi.nlm.nih.gov/14643341/
  16. Marchesan S., et al. “Anti-HIV properties of cationic fullerene derivatives”. Bioorganic and Medicinal Chemistry Letters15 (2005): 3615-3618. https://pubmed.ncbi.nlm.nih.gov/15978810/
  17. Berger CS., et al. “Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma Cells”. Translational Oncology6 (2011): 350-354. https://www.sciencedirect.com/science/article/pii/S1936523311800409
  18. Lai YL., et al. “Fullerene derivative attenuates ischemia-reperfusion-induced lung injury”. Life Sciences11 (2003): 1271-1278. https://pubmed.ncbi.nlm.nih.gov/12570927/
  19. Gonzalez KA., et al. “Synthesis and In vitro characterization of a tissue-selective fullerene: Vectoring C60(OH)16AMBP to mineralized bone”. Bioorganic and Medicinal Chemistry6 (2002): 1991-1997. https://www.sciencedirect.com/science/article/abs/pii/S0968089602000494
  20. Aoshima H., et al. “Antimicrobial activity of fullerenes and their hydroxylated derivatives”. Biocontrol Science2 (2009): 69-72. https://pubmed.ncbi.nlm.nih.gov/19579658/
  21. Lyon DY., et al. “Bacterial cell association and antimicrobial activity of a C60 water suspension”. Environmental Toxicology and Chemistry11 (2005): 2757-2762. https://pubmed.ncbi.nlm.nih.gov/16398110/
  22. Kamat JP., et al. “Reactive oxygen species mediated membrane damage induced by fullerene derivatives and its possible biological implications”. Toxicology1-3 (2000): 55-61. https://europepmc.org/article/med/11154797
  23. Mashino T., et al. “Respiratory chain inhibition by fullerene derivatives: Hydrogen peroxide production caused by fullerene derivatives and a respiratory chain system”. Bioorganic and Medicinal Chemistry7 (2003): 1433-1438. https://www.sciencedirect.com/science/article/abs/pii/S0968089602006107
  24. Dugan LL., et al. “Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons”. Neurobiology of Disease2 (1996): 129-135. https://www.sciencedirect.com/science/article/abs/pii/S0969996196900133
  25. Krusic PJ., et al. “Radical reactions of C60”. Science5035 (1991): 1183-1185. https://pubmed.ncbi.nlm.nih.gov/17776407/
  26. Tokuyama H., et al. “Photoinduced Biochemical Activity of Fullerene Carboxylic Acid”. Journal of the American Chemical Society17 (1993): 7918-7919. https://pubs.acs.org/doi/10.1021/ja00070a064
  27. Pitorre M., et al. “Recent advances in nanocarrier-loaded gels: Which drug delivery technologies against which diseases?” Journal of Controlled Release (2017). https://www.researchgate.net/publication/320006048_Recent_advances_in_nanocarrier-loaded_gels_Which_drug_delivery_technologies_against_which_diseases
  28. Inui S., et al. “Improvement of acne vulgaris by topical fullerene application: Unique impact on skin care”. Nanomedicine: Nanotechnology, Biology, and Medicine2 (2011): 238-241. https://www.researchgate.net/publication/47298365_Improvement_of_acne_vulgaris_by_topical_fullerene_application_Unique_impact_on_skin_care
  29. Fujimoto T., et al. “Induction of different reactive oxygen species in the skin during various laser therapies and their inhibition by fullerene”. Lasers in Surgery and Medicine8 (2012): 685-694. https://pubmed.ncbi.nlm.nih.gov/22899448/
  30. Ryan JJ., et al. “Fullerene Nanomaterials Inhibit the Allergic Response”. The Journal of Immunology1 (2007): 665-672. https://pubmed.ncbi.nlm.nih.gov/17579089/
  31. Gregory GD., et al. “MASTering the immune response: Mast cells in autoimmunity”. In: Novartis Foundation Symposium (2005): 215-225. https://www.researchgate.net/publication/7175104_MASTering_the_Immune_Response_Mast_Cells_in_Autoimmunity
  32. Secor VH., et al. “Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis”. Journal of Experimental Medicine5 (2000): 813-822. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2195850/
  33. Lee DM., et al. “Mast cells: A cellular link between autoantibodies and inflammatory arthritis”. Science5587 (2002): 1689-1692. https://europepmc.org/article/med/12215644
  34. Bradding P., et al. “The role of the mast cell in the pathophysiology of asthma”. Journal of Allergy and Clinical Immunology6 (2006): 1277-1284. https://pubmed.ncbi.nlm.nih.gov/16750987/
  35. Kepley C. “Discovery of A New Mechanism To Control Allergic Asthma Using Fullerene C70 Derivatives”. Journal of Allergy and Clinical Immunology (2012). https://www.jacionline.org/article/S0091-6749(12)00014-0/fulltext
  36. Nozdrenko DM., et al. “C60 Fullerene as Promising Therapeutic Agent for the Prevention and Correction of Skeletal Muscle Functioning at Ischemic Injury”. Nanoscale Research (2017): 115. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309190/
  37. Prylutskyy YI., et al. “C60 fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue”. Journal of Nanobiotechnology1 (2017): 8. https://pubmed.ncbi.nlm.nih.gov/28086894/
  38. Geng H., et al. “Fullerenol nanoparticles suppress RANKL-induced osteoclastogenesis by inhibiting differentiation and maturation”. Nanoscale (2017). https://pubs.rsc.org/en/content/articlelanding/2017/nr/c7nr04365a#!divAbstract
  39. Jiang G., et al. “Synthesis and properties of novel water-soluble fullerene–glycine derivatives as new materials for cancer therapy”. Journal of Materials Science: Materials in Medicine (2015). https://www.researchgate.net/publication/270826098_Synthesis_and_properties_of_novel_water-soluble_fullerene-glycine_derivatives_as_new_materials_for_cancer_therapy
  40. Sosnowska M., et al. “Mechano-signalling, induced by fullerene C60 nanofilms, arrests the cell cycle in the G2/M phase and decreases proliferation of liver cancer cells”. International Journal of Nanomedicine (2019): 6197-6215. https://www.dovepress.com/mechano-signalling-induced-by-fullerene-c60-nanofilms-arrests-the-cell-peer-reviewed-article-IJN
  41. Sukhodub LB., et al. “Fullerene C60-Containing Hydroxyapatite/Polymer Polyelectrolyte Composite for Dental Applications” (2020).
  42. Bakry R., et al. “Medicinal applications of fullerenes”. International Journal of Nanomedicine4 (2007): 639-649. https://pubmed.ncbi.nlm.nih.gov/18203430/
  43. Kerna NA and Flores JV. “The Application of Nanocarbon Onion-Like Fullerene (NOLF) Materials in the Human Respiratory System”. EC Pulmonology and Respiratory Medicine9 (2020): 77-80.
  44. Rodriguez D., et al. “The Protective Effect of Nrf2 Activation in Cardiovascular Disease”. EC Cardiology11 (2019): 78-82. https://www.researchgate.net/publication/336770129_The_Protective_Effect_of_Nrf2_Activation_in_Cardiovascular_Disease
  45. Bosi S., et al. “Fullerene derivatives: An attractive tool for biological applications”. European Journal of Medicinal Chemistry11-12 (2003): 913-923. https://www.sciencedirect.com/science/article/abs/pii/S0223523403001843
  46. Khan ZH and Husain M. “Carbon nanotube and its possible applications”. Indian Journal of Engineering and Materials Sciences (2005). https://www.cheaptubes.com/carbon-nanotubes-properties-and-applications/
  47. Wu W., et al. “Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes”. Angewandte Chemie - International Edition39 (2005): 6358-6362. https://pubmed.ncbi.nlm.nih.gov/16138384/
  48. Li K., et al. “Enhanced antitumor efficacy of doxorubicin-encapsulated halloysite nanotubes”. International Journal of Nanomedicine (2018): 19-30. https://www.dovepress.com/enhanced-antitumor-efficacy-of-doxorubicin-encapsulated-halloysite-nan-peer-reviewed-article-IJN
  49. Grebinyk A., et al. “Complexation with C60 Fullerene Increases Doxorubicin Efficiency against Leukemic Cells In Vitro”. Nanoscale Research Letters (2019). https://nanoscalereslett.springeropen.com/articles/10.1186/s11671-019-2894-1
  50. Zhang W., et al. “The application of carbon nanotubes in target drug delivery systems for cancer therapies”. Nanoscale Research Letters (2011). https://nanoscalereslett.springeropen.com/articles/10.1186/1556-276X-6-555
  51. Hirlekar R., et al. “Review Article Carbon Nanotubes And Its Applications: A Review”. Asian Journal of Pharmaceutics and Clinical research (2009). https://www.researchgate.net/publication/228338965_Carbon_Nanotubes_And_Its_Applications_A_Review
  52. Pradeep KS. “Pharmaceutical Applications of Carbon Nanotube-Mediated Drug Delivery Systems”. International Journal of Pharmaceutical Sciences and Nanotechnology (2012). https://www.researchgate.net/publication/318877226_Pharmaceutical_Applications_of_Carbon_Nanotube-Mediated_Drug_Delivery_Systems
  53. Shinohara H. “Endohedral metallofullerenes”. Reports on Progress in Physics (2000).
  54. He K., et al. “Perfluorohexane-encapsulated fullerene nanospheres for dual-modality US/CT imaging and synergistic high-intensity focused ultrasound ablation”. International Journal of Nanomedicine 14 (2019): 519-529. https://www.dovepress.com/perfluorohexane-encapsulated-fullerene-nanospheres-for-dual-modality-u-peer-reviewed-article-IJN
  55. Wang Y., et al. “Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent”. International Journal of Nanomedicine 15 (2020): 1871-1888. https://www.dovepress.com/experimental-study-of-tumor-therapy-mediated-by-multimodal-imaging-bas-peer-reviewed-article-IJN
  56. Taylor R and Walton DRM. “The chemistry of fullerenes”. Nature (1993): 685-693. https://www.nature.com/articles/363685a0
  57. Hirsch A and Brettreich M. “Fullerenes: Chemistry and Reactions” (2005).
  58. Pirzada M and Altintas Z. “Nanomaterials for Healthcare Biosensing Applications”. Sensors23 (2019): 5311. https://www.mdpi.com/1424-8220/19/23/5311
  59. Liang H., et al. “Functional DNA-containing nanomaterials: cellular applications in biosensing, imaging, and targeted therapy”. Accounts of Chemical Research 6 (2014): 1891-1901. https://pubmed.ncbi.nlm.nih.gov/24780000/
  60. Lee J., et al. “High-Performance Biosensing Systems Based on Various Nanomaterials as Signal Transducers”. Biotechnology Journal 1 (2019): e1800249. https://pubmed.ncbi.nlm.nih.gov/30117715/
  61. Vivero-Escoto JL., et al. “Mesoporous silica nanoparticles for intracellular controlled drug delivery”. Small18 (2010): 1952-1967. https://onlinelibrary.wiley.com/doi/10.1002/smll.200901789
  62. Rosenholm JM., et al. “Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles--opportunities and challenges”. Nanoscale10 (2010): 1870-1883. https://pubmed.ncbi.nlm.nih.gov/20730166/
  63. Tang F., et al. “Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery”. Advanced Materials 12 (2012): 1504-1534. https://onlinelibrary.wiley.com/doi/10.1002/adma.201104763
  64. Anilkumar P., et al. “Fullerenes for applications in biology and medicine”. Current Medicinal Chemistry 14 (2011): 2045-2059. https://www.eurekaselect.com/74034/article/fullerenes-applications-biology-and-medicine
  65. Kumar M and Raza K. “C60-fullerenes as Drug Delivery Carriers for Anticancer Agents: Promises and Hurdles”. Pharmaceutical Nanotechnology 3 (2017): 169-179. https://pubmed.ncbi.nlm.nih.gov/29361902/
  66. Zhou Y., et al. “Construction of Silica-Based Micro/Nanoplatforms for Ultrasound Theranostic Biomedicine”. Advanced Healthcare Materials 18 (2017): 10. https://onlinelibrary.wiley.com/doi/abs/10.1002/adhm.201700646
  67. Li Y., et al. “Cell penetrating peptide-modified nanoparticles for tumor targeted imaging and synergistic effect of sonodynamic/HIFU therapy”. International Journal of Nanomedicine 14 (2019): 6867. https://www.dovepress.com/corrigendum-cell-penetrating-peptide-modified-nanoparticles-for--peer-reviewed-article-IJN
  68. Chen Y., et al. “Nanobiotechnology promotes noninvasive high-intensity focused ultrasound cancer surgery”. Advanced Healthcare Materials 1 (2015): 158-165. https://onlinelibrary.wiley.com/doi/abs/10.1002/adhm.201400127
  69. Sun Y., et al. “Superparamagnetic PLGA-iron oxide microcapsules for dual-modality US/MR imaging and high intensity focused US breast cancer ablation”. Biomaterials24 (2012): 5854-5864. https://pubmed.ncbi.nlm.nih.gov/22617321/
  70. Wang Y., et al. “Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent”. International Journal of Nanomedicine 15 (2020): 1871-1888. https://www.dovepress.com/experimental-study-of-tumor-therapy-mediated-by-multimodal-imaging-bas-peer-reviewed-article-IJN
  71. Chen Y., et al.In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles”. Advanced Materials 23 (2013): 3144-3176. https://pubmed.ncbi.nlm.nih.gov/23681931/
  72. Asefa T and Tao Z. “Biocompatibility of mesoporous silica nanoparticles”. Chemical Research in Toxicology 11 (2012): 2265-2284. https://pubs.acs.org/doi/abs/10.1021/tx300166u
  73. Monteiro-Riviere NA., et al. “Lack of hydroxylated fullerene toxicity after intravenous administration to female Sprague-Dawley rats”. Journal of Toxicology and Environmental Health, Part A 7 (2012): 367-373. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418876/
  74. Johnston HJ., et al. “The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity”. Toxicological Sciences 2 (2010): 162-182. https://www.researchgate.net/publication/38077860_The_Biological_Mechanisms_and_Physicochemical_Characteristics_Responsible_for_Driving_Fullerene_Toxicity
  75. Kerna NA and Flores JV. “The Biocompatibility and Toxicity of Nanocarbon Onion-Like Fullerene (NOLF) Materials in Humans and Living Systems”. EC Pharmacology and Toxicology 9 (2020). https://www.ecronicon.com/ecpt/ECPT-08-00535.php
  76. Gore AC. “Neuroendocrine targets of endocrine disruptors”. Hormones 1 (2010): 16-27. https://pubmed.ncbi.nlm.nih.gov/20363718/
  77. Iavicoli I., et al. “The effects of nanomaterials as endocrine disruptors”. International Journal of Molecular Sciences 8 (2013): 16732-16801. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759935/
Citation: Kerna NA, Flores JV, Pruitt KD, Nwokorie U, Holets H. The Application of Fullerene Derivatives in Medicine and Specific Endocrinological Conditions. EC Endocrinology and Metabolic Research. 2020 Sep 15; 5.11: 56-66.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


June Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the June issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before June 25, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk